On December 18,2022, the "STARHB for Clinical Treatment of hepatitis B"(referred to as "STARHB") was launched in Guangxi.
The project sponsor, Li Mingyang, director of China Liver Health, the leading experts of the project, Professor Gao Zhiliang, Professor Chen Yueyue, Professor Liao Baiming, the First Affiliated Hospital of Guangxi Medical University, and the principals and clinical experts of the co-built base hospital and the co-built sub-center hospital of the "STARHB" gathered in Guangxi. "STARHB" is the first large-scale public welfare project targeting inactive HBeAg negative chronic HBV infected people (referred to as IHC population) in China, aiming to help more chronic hepatitis B infected people get clinical cure, and strive to achieve the goal of "Healthy China 2030" and the World Health Organization 2030 to eliminate the harm of viral hepatitis to human beings. New strategies help clinical cure, and IHC population cannot be ignored At the beginning of 2022, Chinese scholars released the Expert Opinions on Expanding Antiviral Therapy for Chronic Hepatitis B. Academician Zhuang Hui proposed that the treatment trend of chronic hepatitis B is to gradually transition from expanding the treatment standard to a "full treatment" strategy, so that more people with hepatitis B can be included in the treatment range. China's IHC population accounts for a large proportion of more than 30 million people, but it is often neglected because of the hidden and slow progress of the disease. Experts pointed out that the risk of progression to liver cancer in Chinese IHC population is 4.6 times that of healthy population, and the risk of liver cancer in Asian IHC population is 10 times that of European and American population. Therefore, IHC population is a group that can not be ignored for the expanded treatment of hepatitis B. The immune function of the IHC population is good. The previous data shows that the IHC population has a certain probability of clinical cure after treatment with long-acting interferon. Therefore, more evidence-based medical evidence is needed to optimize the cure route, improve the clinical cure rate, and evaluate the benefits and long-term prognosis of patients under different treatment schemes. To this end, initiated by the China Liver Health, Professor Chen Xinyue of Beijing You'an Hospital affiliated to Capital Medical University and Professor Gao Zhiliang of the Third Affiliated Hospital of Sun Yat-sen University jointly launched the "STARHB". With interferon treatment, patients with IHC can obtain a higher clinical cure rate
Professor Gao Zhiliang Professor Gao Zhiliang from the Third Affiliated Hospital of Sun Yat-sen University said that the serological conversion of HBeAg is usually achieved in the IHC population without receiving antiviral treatment, which shows that such patients have good immune status and are more likely to achieve clinical cure. Many research data also confirmed this. Therefore, how to grasp the best treatment opportunity, optimize the cure path, summarize and promote the cure experience is an important issue to be solved urgently for the benefit of the country and the people.
Professor Chen Xinyue Professor Chen Xinyue of Beijing You'an Hospital affiliated to Capital Medical University pointed out that many studies have confirmed the use of pegylated interferon α The treatment of patients with IHC can obtain a high clinical cure rate. Its team's latest meta-analysis found that patients with IHC received pegylated interferon α After 48 weeks of treatment, the clearance rate of HBsAg was as high as 47%, which was significantly better than that of chronic hepatitis B patients. "The study also found that the HBsAg clearance rate will continue to rise after 24 weeks of follow-up after drug withdrawal, and proper prolongation of treatment is beneficial to improve the HBsAg clearance rate." Professor Chen Xinyue said, "pegylated interferon α In the treatment of IHC patients, the clearance rate of HBsAg in 96 weeks is higher than that in 48 weeks, but which group is more suitable for prolonged treatment is still worth further exploration. " The project is planned to benefit 15000 patients, and 15 hospitals in Guangxi were enrolled
Director Li Mingyang Li Mingyang, director of China Liver Health, said that the "STARHB" plan to set up more than 200 project hospitals nationwide, but more than 300 hospitals have signed up to participate. It is planned to enroll 15000 patients with IHC within two years, explore and optimize the treatment path of IHC patients, improve the clinical cure rate, reduce the risk of chronic hepatitis B related cirrhosis and liver cancer, better and more benefit hepatitis B patients, and achieve the goal of hepatitis B clinical cure by accumulating large sample of evidence-based data.
Professor Liao Boming At the meeting, Professor Liao Boming, the First Affiliated Hospital of Guangxi Medical University, read out the list of 15 hospitals. One base hospital is the First Affiliated Hospital of Guangxi Medical University, and 14 sub-center hospitals are: Beihai People's Hospital, Yulin Red Cross Hospital, Guigang People's Hospital, Beihai Hospital of Traditional Chinese Medicine, Hepu County People's Hospital, Baise People's Hospital, Youjiang University of Ethnic Medicine Affiliated Hospital, Qinzhou First People's Hospital, Guangxi University of Traditional Chinese Medicine First Affiliated Hospital, Guangxi University of Traditional Chinese Medicine Affiliated Ruikang Hospital Xing'an County People's Hospital, Guangxi Zhuang Autonomous Region Guidong People's Hospital, Wuzhou Third People's Hospital, Liuzhou Workers' Hospital.
Professor Long Fuli of the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Professor Qin Xiaochao of Yulin Red Cross Hospital, and Ketuo Information Technology Co., Ltd. made further interpretation and guidance on the project plan and implementation. |
关注官方微信 
